(Q42482027)

1 November 2017

title

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution (English)

1 reference

1 November 2017

Raquel S Jallad

1

1 reference

1 November 2017

Nina R C Musolino

series ordinal

2

1 reference

1 November 2017

Luiz R Salgado

series ordinal

3

1 reference

1 November 2017

Marcello D Bronstein

series ordinal

4

1 reference

1 November 2017

publication date

1 August 2005

1 reference

1 November 2017

published in

Clinical Endocrinology

1 reference

1 November 2017

volume

63

1 reference

1 November 2017

issue

2

1 reference

1 November 2017

page(s)

168-175

1 reference

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Criteria for cure of acromegaly: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Octreotide as primary therapy for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Population pharmacodynamic analysis of octreotide in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Primary medical therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02317.X

10.1111/J.1365-2265.2005.02317.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference